Smruthi Organics leaves API as sole operating segment

Smruthi Organics Limited reported that Bulk Drugs and Intermediates was its only operating segment at September 30, 2026, after classifying Formulations Marketing as discontinued; the former division recorded a Rs 7.64 lakh loss after tax for the half year ended on that date, compared with Rs 12.51 lakh a year earlier.

Why has Smruthi Organics classified formulations as discontinued?

Smruthi Organics says its board approved discontinuance of the Formulations Marketing Division at a meeting dated May 13, 2028 in the note to results for the quarter and half year ended September 30, 2026. The results themselves were approved on November 13, 2026, so the filing contains an unexplained date inconsistency. Regardless of that inconsistency, the company states that the division has been classified as a discontinued operation from the stated approval date.

Smruthi Organics presents the formulations unit separately under Indian Accounting Standard 105, or Ind AS 105, covering non-current assets held for sale and discontinued operations. The company says the division’s remaining assets are residual receivables under recovery, stated after a loss allowance. It has consequently disclosed the unit’s current-quarter, half-year and comparative results apart from continuing operations.

What business remains at Smruthi Organics after the exit?

Smruthi Organics says its Bulk Drugs and Intermediates division, labelled API in the filing, was its only operating segment at September 30, 2026. The company therefore says segment reporting is not applicable under Indian Accounting Standard 108, or Ind AS 108, because it had one operating segment at that reporting date.

The continuing-operation figures provide the reported basis for assessing the remaining business. Revenue from operations in the quarter ended September 30, 2026 was Rs 30.71 crore, compared with Rs 31.52 crore in the year-earlier quarter. Total income was Rs 30.73 crore, including Rs 1.87 lakh of other income, while formulations recorded no income in the latest quarter.

How did Smruthi Organics’ discontinued formulations business perform?

Smruthi Organics reported no formulations income for the quarter ended September 30, 2026, versus Rs 7.58 lakh a year earlier. Expenses were Rs 1.39 lakh, resulting in a pre-tax loss of Rs 1.39 lakh and a post-tax loss of Rs 1.04 lakh. In the preceding quarter ended June 30, 2026, the division had Rs 8.82 lakh of expenses and a Rs 6.60 lakh post-tax loss.

For the half year ended September 30, 2026, the division had Rs 10.21 lakh of expenses and a matching pre-tax loss, compared with a Rs 16.72 lakh pre-tax loss in the prior-year half. The post-tax loss narrowed to Rs 7.64 lakh from Rs 12.51 lakh. For the year ended March 31, 2026, formulations reported Rs 24.33 lakh of income, Rs 67.39 lakh of expenses and a Rs 32.22 lakh loss after tax.

The latest half-year result reflects both the absence of reported formulations income and lower expenses. Expenses declined by Rs 27.98 lakh from Rs 38.19 lakh in the half year ended September 30, 2025 to Rs 10.21 lakh in the latest half. The filing does not separately identify the underlying recovery costs, receivables balances or any timetable for completing recovery.

How did Smruthi Organics’ continuing operations change in the half year?

Smruthi Organics reported revenue from operations of Rs 60.01 crore for the half year ended September 30, 2026, up from Rs 50.37 crore in the comparable 2025 period. Profit after tax from continuing operations rose to Rs 4.67 crore from Rs 1.09 crore. These figures exclude the results separately presented for the Formulations Marketing Division.

The cost structure also changed during the six-month period. Material consumption rose to Rs 30.91 crore from Rs 23.09 crore and employee benefit expense increased to Rs 9.08 crore from Rs 8.27 crore. Finance costs fell to Rs 61.65 lakh from Rs 1.12 crore, while profit before tax from continuing operations increased to Rs 6.24 crore from Rs 1.46 crore.

Including the discontinued unit, net profit for the half year was Rs 4.59 crore, compared with Rs 96.07 lakh a year earlier. The difference between continuing-operation profit of Rs 4.67 crore and total net profit reflects the Rs 7.64 lakh formulations loss. Basic earnings per share from continuing operations were Rs 4.08 for the latest half year, against Rs 0.95 in the previous-year half.

What balance-sheet and cash-flow items matter after the exit?

Smruthi Organics reported total assets of Rs 115.06 crore at September 30, 2026, compared with Rs 103.55 crore at March 31, 2026. Inventories increased to Rs 31.98 crore from Rs 28.35 crore and trade receivables rose to Rs 27.14 crore from Rs 19.30 crore. The company does not disclose a separate amount for the residual formulations receivables it says are under recovery.

Cash and cash equivalents were Rs 5.61 lakh at September 30, 2026, down from Rs 1.71 crore at March 31, 2026. During the half year, operating activities generated Rs 6.19 crore, while investing activities used Rs 5.14 crore and financing activities used Rs 2.70 crore. Purchases of fixed assets, intangible assets, capital work-in-progress and capital advances accounted for Rs 5.14 crore of investing outflow.

Current borrowings stood at Rs 8.15 crore at September 30, 2026, versus Rs 5.69 crore at March 31, 2026, while non-current borrowings fell to nil from Rs 2.67 crore. Trade payables to creditors other than micro and small enterprises rose to Rs 19.37 crore from Rs 13.77 crore. These balance-sheet movements are reported alongside the shift to a single operating segment.

Conclusion

Smruthi Organics has separated the Formulations Marketing Division from continuing operations and identifies Bulk Drugs and Intermediates as its sole operating segment at September 30, 2026. The discontinued unit produced no reported income in the latest quarter and a Rs 7.64 lakh half-year loss after tax, while continuing operations reported Rs 4.67 crore of half-year profit after tax.

The next disclosures to watch are the recovery of residual formulations receivables, which the company says are carried after a loss allowance but does not quantify separately, and clarification of the May 13, 2028 board-meeting date in a filing issued on November 13, 2026. Future results will also show whether the Rs 60.01 crore half-year revenue from the remaining operation is sustained.